Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A. Vogel; A. Cervantes; I. Chau; B. Daniele; J. Llovet; T. Meyer; J. C. Nault; U. Neumann; J. Ricke; B. Sangro; P. Schirmacher; C. Verslype; C. J. Zech; D. Arnold; E. Martinelli

doi:10.1093/annonc/mdy308

Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. Llovet, T. Meyer, J. C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold, E. Martinelli

Research output: Contribution to journal › Article › peer-review

553 Scopus citations

Original language	English
Pages (from-to)	iv238-iv255
Journal	Annals of Oncology
Volume	29
DOIs	https://doi.org/10.1093/annonc/mdy308
State	Published - 1 Oct 2018

Access to Document

10.1093/annonc/mdy308

Cite this

Vogel, A., Cervantes, A., Chau, I., Daniele, B., Llovet, J., Meyer, T., Nault, J. C., Neumann, U., Ricke, J., Sangro, B., Schirmacher, P., Verslype, C., Zech, C. J., Arnold, D., & Martinelli, E. (2018). Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29, iv238-iv255. https://doi.org/10.1093/annonc/mdy308

@article{f3519f7b21fd491fa48e675a2dec34cc,

title = "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up",

author = "A. Vogel and A. Cervantes and I. Chau and B. Daniele and J. Llovet and T. Meyer and Nault, {J. C.} and U. Neumann and J. Ricke and B. Sangro and P. Schirmacher and C. Verslype and Zech, {C. J.} and D. Arnold and E. Martinelli",

note = "Funding Information: AV has received honoraria for talks and advisory boards from Bayer, Roche, Lilly, Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Eisai, Novartis and Ipsen; AC has provided consulting and advisory services for Merck Serono, Amgen, Servier, Roche, Lilly, Novartis, Takeda and Astellas and has received research support from Roche, Merck Serono, Servier, Beigene and Astellas; IC has reported being a member of the advisory boards of Eli-Lilly, Bristol-Myers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics and Astra-Zeneca and has received research funding from Eli-Lilly, Janssen-Cilag, Sanofi Oncology, Merck-Serono and honorarium from Eli-Lilly; BD has received honoraria or consultation fees from Bayer, Bristol-Myers Squibb, MSD, Merck KGaA, Ipsen, Eisai and Lilly; JL has received consultancy fees from Bayer, Bristol-Myers Squibb, Incyte, Lilly, Eisai, Celsion, Glycotest, Ipsen, Merck and Exelixis and research support from Incyte, Bayer, Bristol-Myers Squibb and Eisai; TM has received consulting fees from Bristol-Myers Squibb, Bayer, Eisai, Ipsen, Merck, BTG and Beigene; UN has given presentations for Merck, Amgen, Roche, Gr{\"u}nenthal and Bayer on topics other than HCC; JR has received consulting fees and research grants from Bayer Healthcare and Sirtex Medical; BS has received consulting and/or lecture fees from Adaptimmune, AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Onxeo, Sirtex and Terumo; PS has reported being a member of advisory board and has received grants from Novartis and Bristol-Myers Squibb; CV has received consultancy fees and re-19. search funding from Bayer, Sirtex, Novartis and Ipsen; CJZ has received honoraria for lectures and advisory boards by Bayer Healthcare; DA has received honoraria for consultancy from Roche, Merck Serono, Bayer Healthcare, Servier, BTG, Terumo, Sanofi Oncology and Eli Lilly; EM has received honoraria for lecture and advisory boards for Roche, Amgen, Servier and Sanofi; JCN has reported no conflicts of interest.",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy308",

language = "English",

volume = "29",

pages = "iv238--iv255",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

}

TY - JOUR

T1 - Hepatocellular carcinoma

T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

AU - Vogel, A.

AU - Cervantes, A.

AU - Chau, I.

AU - Daniele, B.

AU - Llovet, J.

AU - Meyer, T.

AU - Nault, J. C.

AU - Neumann, U.

AU - Ricke, J.

AU - Sangro, B.

AU - Schirmacher, P.

AU - Verslype, C.

AU - Zech, C. J.

AU - Arnold, D.

AU - Martinelli, E.

N1 - Funding Information: AV has received honoraria for talks and advisory boards from Bayer, Roche, Lilly, Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Eisai, Novartis and Ipsen; AC has provided consulting and advisory services for Merck Serono, Amgen, Servier, Roche, Lilly, Novartis, Takeda and Astellas and has received research support from Roche, Merck Serono, Servier, Beigene and Astellas; IC has reported being a member of the advisory boards of Eli-Lilly, Bristol-Myers Squibb, MSD, Bayer, Roche, Merck-Serono, Five Prime Therapeutics and Astra-Zeneca and has received research funding from Eli-Lilly, Janssen-Cilag, Sanofi Oncology, Merck-Serono and honorarium from Eli-Lilly; BD has received honoraria or consultation fees from Bayer, Bristol-Myers Squibb, MSD, Merck KGaA, Ipsen, Eisai and Lilly; JL has received consultancy fees from Bayer, Bristol-Myers Squibb, Incyte, Lilly, Eisai, Celsion, Glycotest, Ipsen, Merck and Exelixis and research support from Incyte, Bayer, Bristol-Myers Squibb and Eisai; TM has received consulting fees from Bristol-Myers Squibb, Bayer, Eisai, Ipsen, Merck, BTG and Beigene; UN has given presentations for Merck, Amgen, Roche, Grünenthal and Bayer on topics other than HCC; JR has received consulting fees and research grants from Bayer Healthcare and Sirtex Medical; BS has received consulting and/or lecture fees from Adaptimmune, AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Onxeo, Sirtex and Terumo; PS has reported being a member of advisory board and has received grants from Novartis and Bristol-Myers Squibb; CV has received consultancy fees and re-19. search funding from Bayer, Sirtex, Novartis and Ipsen; CJZ has received honoraria for lectures and advisory boards by Bayer Healthcare; DA has received honoraria for consultancy from Roche, Merck Serono, Bayer Healthcare, Servier, BTG, Terumo, Sanofi Oncology and Eli Lilly; EM has received honoraria for lecture and advisory boards for Roche, Amgen, Servier and Sanofi; JCN has reported no conflicts of interest.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85054346991&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy308

DO - 10.1093/annonc/mdy308

M3 - Article

C2 - 30285213

AN - SCOPUS:85054346991

SN - 0923-7534

VL - 29

SP - iv238-iv255

JO - Annals of Oncology

JF - Annals of Oncology

ER -